China Medical Technologies, Inc.
US Elections Calendar ~ Pervez Musharraf ~ Iftikhar Muhammad Chaudhry ~ Other International News
Home / International News / Press Releases / March 24, 2008
China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents

Top News

Andhra Pradesh SSC 2008 Results

Rededication Day marks Congress Government's fourth year in office

60 per cent voting recorded in second phase of Karnataka polls

Kids admit violent video games make them aggressive

Ellen DeGeneres announces plan to marry Portia de Rossi

Turkish Petroleum Company plans exploration work in the Mediterranean

Manchester bans big screens for Champion League Final fearing violence

E-mail petitions dont spread like viral

Disabling enzyme raises fertility levels by 50pc in mice

China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents

BEIJING, March 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in- vitro diagnostic ("IVD") products and high intensity focused ultrasound tumor therapy systems, today announces that the Company receives the Conformite Europeenne Mark ("CE Mark") for its two semi-automatic ECLIA analyzers and 15 reagents.

Under the In-Vitro Diagnostic Directive ("IVDD") of the European Union ("EU"), products must meet regulatory requirements in order to qualify for sales and distributions in the EU. A CE Mark indicates that a product complies with the EU regulatory requirements. The Company receives the CE Mark for its two semi-automatic ECLIA analyzers and 15 reagents, including thyroid disorders, diabetes and tumor marker reagents.

"The CE Mark demonstrates that our products meet the IVDD requirements," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "It not only allows us access to new markets but also strengthens our leading position in the advanced IVD market in China."

ECLIA system is a closed IVD system including an analyzer and reagents that are used to detect and quantify particular antibodies or antigens for the diagnosis and analysis of various diseases and disorders. The Company will continue to work on receiving CE Mark for its other ECLIA reagents.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

    For more information, please contact:

     China Medical Technologies, Inc.
     Winnie Fan
     Email: IR@chinameditech.com

SOURCE China Medical Technologies, Inc.

International News / Press Release source: PR Newswire
Copyright PR Newswire. All Rights Reserved.

International Business News / Press Releases

WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
PR Newswire

Beijing Komoxo Mobile Software Licenses Patents From Microsoft
PR Newswire

The Conference Board(R) Australia Business Cycle Indicators(SM)
PR Newswire

Martin Froggatt to Succeed Paul Barry as President of Europe Express
PR Newswire

Boeing, Lion Air Celebrate 10th 737-900ER Delivery
PR Newswire

International Health News / Press Releases

WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
PR Newswire

Death Toll From Recalled Chinese Heparin Continues to Rise; Tainted Heparin Still in Circulation
PR Newswire

Hoya Announces Fourth Quarter and FY2007 Financial Results
PR Newswire

Lupin Announces Launch of Suprax(R) 400mg Tablets
PR Newswire

Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
PR Newswire

International Medical News / Press Releases

WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
PR Newswire

Terumo, Global Medical Technology Company, Opens Office in Switzerland
PR Newswire

HeartWare Appoints David R. Hathaway, M.D. Chief Medical Officer
PR Newswire

Hoya Announces Fourth Quarter and FY2007 Financial Results
PR Newswire

Lupin Announces Launch of Suprax(R) 400mg Tablets
PR Newswire